Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Olga Petryna DrPetryna
3 years 1 month ago
#acrbest #abst0004 #acr22 @rheumnow 🐁 model of excessive mTORC1 activation in JIA confirms unrestricted activation of mTORC1 sufficient to trigger sJIA-like syndrome including MAS w/hemophagocytosis. rapamycin prevents MAS & ⬇️ arthritis severity & bone erosion in Il1rn-/- mice https://t.co/2HSXOJ6tX8
David Liew drdavidliew
3 years 1 month ago
If rheumatologists were distributed equitably in the US, the Navajo nation should have 19 rheumatologists.
They have just one.
Very exciting scalable program to empower primary care. Enormously powerful, both there and elsewhere
ABST0005 @jrmandal @JYazdanyMD #ACR22 @RheumNow https://t.co/mOtgLomZLM
Julian Segan JulianSegan
3 years 1 month ago
Only small changes in lipid profile and no change in arterial inflammation (measured by FDG-PET) in both TNFi/MTX and triple therapy groups over a 24 week period in the TARGET trial.
What do you think could account for this? Follow-up period too short?
@RheumNow ABST0254 #ACR22 https://t.co/JMJ7WgXyJX
Dr. John Cush RheumNow
3 years 1 month ago
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty.
TheDaoIndex KDAO2011
3 years 1 month ago
What's better, #cyclophosphamide or #rituximab in CT-ILD? The RECITAL Trial noted both work, but CYP had more GI side effects (not surprising). The study was just published in NEJM. QR code in image to view.
#plenary abst#003 @rheumnow #ACR22 https://t.co/ZDIWtlc9dY
Robert B Chao, MD doctorRBC
3 years 1 month ago
Important to remember to screen for cancer in patients with idiopathic inflammatory myopathy, esp in high risk pts! Can even consider PET/CT, CT, pelvic US, initially. Question is... will insurances approve all of these tests?
Abs#0002 @RheumNow #ACR22 https://t.co/uvr4jGVTFP
TheDaoIndex KDAO2011
3 years 1 month ago
Consensus for #cancer screening in IIM Presented: For more info, go to this session #CurbsideConsults #ACR22 @rheumnow #myositis https://t.co/vJ82rEX2wk
Mike Putman EBRheum
3 years 1 month ago
Pooled data from belimumab RCTs w/>3,000 pts evaluating kidney outcomes vs PLBO
Tagging off BLISS-LN, pooled analysis w/marginal but real benefit to adding BEL in pts with SLE
I offer this to all pts w/SLE LN on MMF, but I do not push it
#ACRbest #ACR22 @RheumNow #0352 https://t.co/QYGgB3ue36
TheDaoIndex KDAO2011
3 years 1 month ago
Consensus for #cancer screening in IIM Presented: When to Go Beyond Standard and Extended Screening #Plenary #ACR22 @rheumnow #myositis #ExpertOpinionNotData https://t.co/cL6zrMnzT3
David Liew drdavidliew
3 years 1 month ago
Cancer screening in myositis:
the path has always been unclear and inconsistent
Workable consensus recommendations @Dr_Alex_Oldroyd
risk stratification but still extensive investigation burden for most
now need to look at effectiveness including cost
ABST0002 #ACR22 @RheumNow https://t.co/322qnGjB9K
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#0002 @Dr_Alex_Oldroyd presented eminence-based recommendation for patients with inflammatory myopathy. Enhanced screening for those high risk. Studies needed to assess feasibility i.e. cost, positive and negative predictive value of test etc. @RheumNow https://t.co/G1MyQDMhOa
TheDaoIndex KDAO2011
3 years 1 month ago
Consensus for #cancer screening in IIM Presented: How Often to Screen #Plenary #ACR22 @rheumnow #myositis https://t.co/h1kp7Z9ynO
TheDaoIndex KDAO2011
3 years 1 month ago
Consensus for #cancer screening in IIM Presented: What tests to order for screening #Plenary #ACR22
@rheumnow #myositis https://t.co/pPLcsFLtG9
TheDaoIndex KDAO2011
3 years 1 month ago
Consensus for CA screening in IIM Presented: Risk factors to consider screening
#Plenary #ACR22 @rheumnow #myositis https://t.co/CDNPaRUpPS
Julian Segan JulianSegan
3 years 1 month ago
Risk stratification for cancer in myositis
@RheumNow #ACR22 #Plenary https://t.co/j7R7P3PS7c
Poster Hall